21 July 2026

India gives nod to first dengue vaccine for 4- to 60-year-olds

Logo
Bangla Press Published: 21 July 2026, 12:26 AM
India gives nod to first dengue vaccine for 4- to 60-year-olds

Bangla Press Desk:  The Drug Controller General of India (DCGI) has granted market authorisation to Takeda Biopharmaceuticals India’s QDENGA (TAK-003), making it the first dengue vaccine to be approved in the country, according to a press release issued by the company.

The vaccine has been approved for the prevention of dengue disease in individuals aged 4 to 60 years. QDENGA is a live-attenuated tetravalent vaccine designed to provide protection against all four dengue virus serotypes and is administered as a two-dose regimen, with doses given three months apart.

According to the company, the vaccine can be administered irrespective of whether an individual has had a previous dengue infection and does not require pre-vaccination screening. The approval comes as dengue continues to pose a significant public health challenge in India, where reported cases have increased nearly 11-fold over the past two decades. India accounts for nearly one-third of the global dengue burden, although modelling studies suggest the actual number of infections is substantially higher than reported.

The approval is based on Takeda’s global clinical development programme comprising 19 Phase I, II and III clinical trials involving more than 28,000 participants in dengue-endemic and non-endemic regions.

The company’s pivotal Phase III TIDES (DEN-301) trial enrolled more than 20,000 participants across eight dengue-endemic countries. According to Takeda, the vaccine demonstrated an efficacy of 80.2% against virologically confirmed dengue 12 months after the second dose and 90.4% efficacy against dengue-related hospitalisation at 18 months. Follow-up data at 4.5 years showed 84.1% efficacy against dengue-related hospitalisation, while seven-year follow-up demonstrated sustained protection against dengue disease and dengue-related hospitalisation across all four serotypes.https://www.daily-sun.com/world/887676/india-approves-first-dengue-vaccine-for-individuals-aged-4-to-60-years#:~:text=The%20approval%20in,vaccine%20in%20India.

[Bangla Press is a global platform for free thought. It provides impartial news, analysis, and commentary for independent-minded individuals. Our goal is to bring about positive change, which is more important today than ever before.]

Comments (0)

Join the Conversation

Please log in to share your thoughts and engage with other readers.

No comments yet

Be the first to share your thoughts on this article!

Sangeet Academy


Sangeet Academy